100.00% -1.90

Atyr Pharma Inc (LIFE)

Atyr Pharma Inc Borsa (LIFE) Ultime notizie

Atyr Pharma Inc (LIFE)

Atyr Pharma Inc Borsa (LIFE) Ultime notizie

Short Interest in Atyr PHARMA INC (NASDAQ:ATYR) Grows By 27.1% - MarketBeat

Jefferies initates Atyr Pharma Inc (ATYR) rating to a Buy - Knox Daily

ATYR’s 2023 Market Dance: Up 33.33% – Time to Invest? - The InvestChronicle

aTyr Pharma: Two 2025 Data Readouts Could Provide Inflection Point - Seeking Alpha

Atyr Pharma Inc [ATYR] Records 50-Day SMA of $1.7995 - Knox Daily

Examining Atyr Pharma Inc (ATYR) more closely is necessary - US Post News

Ratios Uncovered: Breaking Down Atyr Pharma Inc (ATYR)’s Trailing Twelve Months Metrics - The Dwinnex

Atyr PHARMA (NASDAQ:ATYR) Coverage Initiated by Analysts at Jefferies Financial Group - Defense World

Jefferies says 'Buy' on aTyr Pharma stock, citing potential breakthrough in pulmonary sarcoidosis - Investing.com Canada

Atyr PHARMA (NASDAQ:ATYR) Now Covered by Jefferies Financial Group - MarketBeat

Jefferies Initiates Coverage of aTyr Pharma (ATYR) with Buy Recommendation - MSN

Critical Comparison: Atyr PHARMA (ATYR) and Its Competitors - Defense World

Is Atyr Pharma Inc (ATYR) positioned for future growth? - SETE News

Critical Comparison: Atyr PHARMA (ATYR) versus Its Peers - Defense World

Analyzing Atyr PHARMA (ATYR) & The Competition - Defense World

Financial Comparison: Atyr PHARMA (ATYR) vs. Its Rivals - Defense World

Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 28.2% in August - MarketBeat

aTyr Pharma, Inc. (NASDAQ:ATYR) is largely controlled by institutional shareholders who own 61% of the company - Yahoo Finance UK

aTyr Pharma to Participate in September Investor Conferences - GlobeNewswire

aTyr Pharma to Participate in September Investor Conferences - StockTitan

ATYR (aTyr Pharma) 3-Year EBITDA Growth Rate : 15.30% (As of Jun. 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 20, 2024) - GuruFocus.com

Atyr Pharma Inc (ATYR) rating downgrades by Oppenheimer - Knoxdaily.com

Atyr Pharma Inc (ATYR)’s highs and lows: A closer look at its stock price fluctuations - US Post News

Investor’s Delight: Atyr Pharma Inc (ATYR) Closes Weak at 1.91, Down -4.50 - The Dwinnex

aTyr Pharma (STU:471A) Inventory-to-Revenue : 0.00 (As of Jun. 2024) - GuruFocus.com

ATYR (aTyr Pharma) Volatility : 53.54% (As of Aug. 19, 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Total Inventories : €0.00 Mil (As of Jun. 2024) - GuruFocus.com

aTyr Pharma (STU:471A) Enterprise Value : €73.04 Mil (As of Aug. 18, 2024) - GuruFocus.com

aTyr Pharma (FRA:471A) Float Percentage Of Total Shares Out - GuruFocus.com

aTyr Pharma (FRA:471A) Peter Lynch Fair Value : €-21.05 (As of Aug. 17, 2024) - GuruFocus.com

ATYR (aTyr Pharma) Short-Term Debt & Capital Lease Obligati - GuruFocus.com

Atyr PHARMA INC (NASDAQ:ATYR) Short Interest Update - MarketBeat

Atyr PHARMA (NASDAQ:ATYR) Rating Reiterated by HC Wainwright - Defense World

Atyr PHARMA INC (NASDAQ:ATYR) to Post Q3 2024 Earnings of ($0.22) Per Share, HC Wainwright Forecasts - Defense World

Q3 2024 Earnings Forecast for Atyr PHARMA INC Issued By HC Wainwright (NASDAQ:ATYR) - MarketBeat

ATYR’s Stock Market Adventure: 41.84% YTD Growth Amidst Volatility - The InvestChronicle

ATYR (aTyr Pharma) Cash From Discontinued Investing Activit - GuruFocus.com

Is aTyr Pharma (NASDAQ:ATYR) In A Good Position To Invest In Growth? - Yahoo Finance

HC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR) - MarketBeat

Atyr PHARMA INC to Post FY2028 Earnings of $4.72 Per Share, HC Wainwright Forecasts (NASDAQ:ATYR) - Defense World

Atyr PHARMA (NASDAQ:ATYR) Receives “Outperform” Rating from Royal Bank of Canada - Defense World

Atyr PHARMA (NASDAQ:ATYR) Issues Earnings Results, Beats Expectations By $0.01 EPS - Defense World

Atyr PHARMA (NASDAQ:ATYR) Announces Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat

Atyr PHARMA (NASDAQ:ATYR) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Piper Sandler maintains Overweight rating on aTyr Pharma shares By Investing.com - Investing.com UK

Atyr Pharma: Q2 Earnings Snapshot - CT Insider

Atyr Pharma: Q2 Earnings Snapshot - Darien Times

Atyr Pharma: Q2 Earnings Snapshot - CTPost

ATYR (aTyr Pharma) Profitability Rank : 1 (As of Mar. 2024) - GuruFocus.com

ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024 - InvestorPlace

ATYR Stock Earnings: aTyr Pharma Beats EPS for Q2 2024 - MSN

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update - BioSpace

ATYR (aTyr Pharma) 3-Year EPS without NRI Growth Rate : 19.00% (As of Mar. 2024) - GuruFocus.com

Atyr Pharma: Q2 Earnings Snapshot - Houston Chronicle

Atyr Pharma: Q2 Earnings Snapshot - Thehour.com

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update - wallstreet:online

Atyr Pharma: Q2 Earnings Snapshot - San Antonio Express-News

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update - GlobeNewswire

aTyr Pharma Announces Second Quarter 2024 Results and Provides Corporate Update - StockTitan

Sarcoidosis Drugs Market Size 2032 | Pfizer, United - openPR

Taking a Closer Look At Atyr Pharma Inc (ATYR) Following Its Recent Trade - Knox Daily

Interstitial Lung Disease Pipeline 2024 | Roche, aTyr Pharma, - openPR

The Globe and Mail - The Globe and Mail

Quarterly Metrics: Quick and Current Ratios for Atyr Pharma Inc (ATYR) - The Dwinnex

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations - GlobeNewswire

aTyr Pharma Announces Appointment of Jayant Aphale, PhD, as Vice President of Technical Operations - StockTitan

Examining Atyr Pharma Inc (ATYR) stock is warranted - US Post News

Simile a LIFE